Want to see VTRS full AI Analyst Report?
Earnings Data
Report Date
Aug 06, 2026Before Open (Confirmed)
Period Ending
2026 (Q2)Consensus EPS Forecast
0.6Last Year’s EPS
0.62Same Quarter Last Year
Based on 6 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Positive
The call portrayed solid operational performance and momentum: top-line revenue growth (3%), strong adjusted EBITDA expansion (10%), sizable China acceleration (+18%), meaningful pipeline progress with multiple upcoming regulatory catalysts, and robust cash flexibility (> $2.5B). These positives were tempered by regional softness (Europe, JANZ), supply constraints in lower-margin generics/ARV, ongoing regulatory timing uncertainty, and policy risk in China. On balance, the positives (broad-based execution, margin control, late-stage pipeline momentum and financial flexibility) outweigh the lowlights.Company Guidance
Revenue Growth and Profitability
Total revenues of $3.5 billion, up 3% year-over-year (operational basis); adjusted EBITDA of $1.0 billion (10% growth year-over-year) and adjusted EPS of $0.59, demonstrating improved earnings leverage versus revenue growth.
Strong Greater China Performance
Greater China revenue accelerated 18% year-over-year, driven by favorable market fundamentals, strategic commercial investments and e-commerce growth (e-commerce sales more than doubled vs. prior year). Company raised its China growth expectation for 2026 to mid- to high-single digits.
Robust Pipeline Progress and Near-Term Catalysts
Regulatory approval received for EFFEXOR for GAD in Japan; NDA for fast-acting meloxicam accepted by FDA and XULANE LO (low-dose estrogen patch) expected PDUFA July 30, 2026; phentolamine sNDA PDUFA Oct 17, 2026. Company remains on track for 5 additional regulatory decisions in H2 2026 and multiple launches expected to accelerate growth.
Clinical Program Momentum in Late-Stage Programs
Selatogrel SOS-AMI Phase III enrollment ~1,200 patients per month and on track potentially to reach full enrollment by end of 2026; cenerimod Phase III SLE OPUS-1 and 2 fully enrolled with results expected in H1 2027 — representing material longer-term growth opportunities.
New Product Revenue Contribution and Complex Generics
New product revenue contribution of $71 million in the quarter (including launches of iron sucrose and octreotide); secured approval of a generic to Abilify Maintena and positioned for U.S. launch before year-end; on-track for FDA decisions this year on other complex generics (e.g., ferric carboxymaltose injection, rotigotine patch).
Margin and Cost Management
Adjusted gross margin of 56% (flat year-over-year) with margins slightly better than expected due to favorable product mix; operating expenses favorable versus prior year reflecting disciplined cost management and early realization of enterprise-wide strategic review savings (on track to deliver planned savings).
Strong Cash Generation and Capital Flexibility
Generated $348 million of cash in the quarter (or ~$459 million excluding transaction/restructuring costs and taxes); returned $140 million to shareholders via dividend; expecting more than $2.5 billion of cash available for deployment during 2026 to support dividends, buybacks, BD and reinvestment.
Clinical and Regulatory Evidence Supporting Label Expectations
Company believes data support inclusion of opioid-sparing language for fast-acting meloxicam label and presented positive Phase III and other data across programs (e.g., XULANE LO adhesion and PK data presented at ACOG).
Product-Specific Data and Development Wins
Creon Phase III interim analysis in non-cystic fibrosis patients showed ~76% of patients inadequately treated on current approved dose benefitted from dose escalation; plans to file a type 2 variation in Europe before year-end to drive future growth and label update in H1 2027.
Reaffirmed Guidance and Second-Half Weighting
Management reaffirmed 2026 guidance ranges and expects total revenues, adjusted EBITDA and adjusted EPS to be weighted to the second half (~52% of full-year outlook) reflecting seasonality and timing of launches.
VTRS Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
VTRS Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
May 07, 2026 | $15.83 | $17.26 | +9.03% |
Feb 26, 2026 | $15.83 | $15.01 | -5.16% |
Nov 06, 2025 | $10.46 | $9.84 | -5.95% |
Aug 07, 2025 | $8.42 | $9.03 | +7.31% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Viatris, Inc. (VTRS) report earnings?
Viatris, Inc. (VTRS) is schdueled to report earning on Aug 06, 2026, Before Open (Confirmed).
What is Viatris, Inc. (VTRS) earnings time?
Viatris, Inc. (VTRS) earnings time is at Aug 06, 2026, Before Open (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is VTRS EPS forecast?
VTRS EPS forecast for the fiscal quarter 2026 (Q2) is 0.6.
